Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,637 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
FDA-approved disulfiram as a novel treatment for aggressive leukemia.
Karsa M, Xiao L, Ronca E, Bongers A, Spurling D, Karsa A, Cantilena S, Mariana A, Failes TW, Arndt GM, Cheung LC, Kotecha RS, Sutton R, Lock RB, Williams O, de Boer J, Haber M, Norris MD, Henderson MJ, Somers K. Karsa M, et al. Among authors: de boer j. J Mol Med (Berl). 2024 Apr;102(4):507-519. doi: 10.1007/s00109-023-02414-4. Epub 2024 Feb 13. J Mol Med (Berl). 2024. PMID: 38349407 Free PMC article.
Direct targeted therapy for MLL-fusion-driven high-risk acute leukaemias.
Cantilena S, Gasparoli L, Pal D, Heidenreich O, Klusmann JH, Martens JHA, Faille A, Warren AJ, Karsa M, Pandher R, Somers K, Williams O, de Boer J. Cantilena S, et al. Among authors: de boer j. Clin Transl Med. 2022 Jun;12(6):e933. doi: 10.1002/ctm2.933. Clin Transl Med. 2022. PMID: 35730653 Free PMC article.
Alcohol-abuse drug disulfiram targets pediatric glioma via MLL degradation.
Meier S, Cantilena S, Niklison Chirou MV, Anderson J, Hargrave D, Salomoni P, de Boer J, Michod D. Meier S, et al. Among authors: de boer j. Cell Death Dis. 2021 Aug 11;12(8):785. doi: 10.1038/s41419-021-04078-9. Cell Death Dis. 2021. PMID: 34381018 Free PMC article.
Identification of a c-MYB-directed therapeutic for acute myeloid leukemia.
Clesham K, Walf-Vorderwülbecke V, Gasparoli L, Virely C, Cantilena S, Tsakaneli A, Inglott S, Adams S, Samarasinghe S, Bartram J, Williams G, de Boer J, Williams O. Clesham K, et al. Among authors: de boer j. Leukemia. 2022 Jun;36(6):1541-1549. doi: 10.1038/s41375-022-01554-9. Epub 2022 Apr 2. Leukemia. 2022. PMID: 35368048 Free PMC article.
In focus: MLL-rearranged leukemia.
de Boer J, Walf-Vorderwülbecke V, Williams O. de Boer J, et al. Leukemia. 2013 Jun;27(6):1224-8. doi: 10.1038/leu.2013.78. Epub 2013 Mar 21. Leukemia. 2013. PMID: 23515098 Review.
Frat2 mediates the oncogenic activation of Rac by MLL fusions.
Walf-Vorderwülbecke V, de Boer J, Horton SJ, van Amerongen R, Proost N, Berns A, Williams O. Walf-Vorderwülbecke V, et al. Among authors: de boer j. Blood. 2012 Dec 6;120(24):4819-28. doi: 10.1182/blood-2012-05-432534. Epub 2012 Oct 16. Blood. 2012. PMID: 23074275 Free article.
ERG is a megakaryocytic oncogene.
Salek-Ardakani S, Smooha G, de Boer J, Sebire NJ, Morrow M, Rainis L, Lee S, Williams O, Izraeli S, Brady HJ. Salek-Ardakani S, et al. Among authors: de boer j. Cancer Res. 2009 Jun 1;69(11):4665-73. doi: 10.1158/0008-5472.CAN-09-0075. Cancer Res. 2009. PMID: 19487285
1,637 results